Contact your doctor immediately if you experience: Severe, persistent abdominal pain that may indicate pancreatitis, particularly if radiating to the back or accompanied by vomiting Signs of gallbladder disease , including right upper quadrant pain, fever, jaundice, or clay-colored stools (cholelithiasis rates in clinical trials range from approximately 0.6% to 2.5%, depending on dose and duration) Symptoms of acute kidney injury , such as decreased urination, swelling, fatigue, or confusion, especially if accompanied by dehydration Visual changes , including blurred vision or difficulty focusing, which may indicate diabetic retinopathy complications (rapid glycemic improvement with tirzepatide can temporarily worsen retinopathy) Severe allergic reactions , including rash, itching, swelling of face or throat, severe dizziness, or difficulty breathing Persistent vomiting or diarrhea lasting more than 24 hours, which increases dehydration and acute kidney injury risk Symptoms suggesting thyroid tumors , including neck mass, hoarseness, dysphagia, or dyspnea New or worsening depression, suicidal thoughts, or unusual changes in mood or behavior , particularly in patients taking Zepbound for weight management Routine monitoring should include periodic assessment of renal function, particularly in patients with pre-existing kidney disease or those experiencing significant gastrointestinal symptoms

However, doses should typically be spaced at least 72 hours apart
You may not be eligible if you: Have a BMI over 35 Have uncontrolled heart, metabolic, or cognitive conditions Use insulin, or medications that significantly affect weight Are planning major lifestyle changes (e.g., starting keto or intensive workouts) Have a history of eating disorders, bariatric surgery, or pancreatitis Are taking certain hormones, steroids, or investigational medications Are pregnant, nursing, or planning pregnancy (or capable of pregnancy without contraception) Well go over the full list with you during the screening
Nonetheless, both studies report improved effector function of CD8 T cells upon treatment with butyrate, as demonstrated by the increased production of IFN- and TNF- in vivo